[{"id":"7cd7c85e-4e1b-46fd-8491-96d1bcc8b391","acronym":"IMGN632-0802","url":"https://clinicaltrials.gov/study/NCT04086264","created_at":"2021-01-18T20:00:09.580Z","updated_at":"2025-02-25T12:27:19.012Z","phase":"Phase 1/2","brief_title":"IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia","source_id_and_acronym":"NCT04086264 - IMGN632-0802","lead_sponsor":"AbbVie","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • pivekimab sunirine (PVEK)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 218","initiation":"Initiation: 11/06/2019","start_date":" 11/06/2019","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-24"},{"id":"a3758200-2675-4c3a-9e8c-8a19c87396ef","acronym":"","url":"https://clinicaltrials.gov/study/NCT04230265","created_at":"2023-08-14T10:11:02.629Z","updated_at":"2025-02-25T15:43:50.590Z","phase":"Phase 1","brief_title":"Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies","source_id_and_acronym":"NCT04230265","lead_sponsor":"AvenCell Europe GmbH","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AVC-101"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-11"},{"id":"9436a8ff-5aa6-4f94-a70c-ecf2cecaa874","acronym":"NCI-2022-02215","url":"https://clinicaltrials.gov/study/NCT05285813","created_at":"2023-08-14T10:11:07.915Z","updated_at":"2024-07-02T16:34:58.922Z","phase":"Phase 2","brief_title":"A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure","source_id_and_acronym":"NCT05285813 - NCI-2022-02215","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vibecotamab (XmAb14045)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 05/06/2022","start_date":" 05/06/2022","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-06-04"},{"id":"619771d1-d4a0-44c2-8ac6-1aa798882b7f","acronym":"TAGALONG","url":"https://clinicaltrials.gov/study/NCT05442216","created_at":"2023-08-14T10:11:09.139Z","updated_at":"2024-07-02T16:35:06.443Z","phase":"Phase 2","brief_title":"Tagraxofusp and Azaxitadine With or Without Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents","source_id_and_acronym":"NCT05442216 - TAGALONG","lead_sponsor":"Joshua Zeidner","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Elzonris (tagraxofusp-erzs)"],"overall_status":"Recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-05-02"},{"id":"ac11fef2-00de-4d70-b80b-5c5887b96c6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05817058","created_at":"2023-08-14T10:11:11.877Z","updated_at":"2024-07-02T16:35:14.822Z","phase":"Phase 1","brief_title":"First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT05817058","lead_sponsor":"Affimed GmbH","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFM28"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 03/21/2023","start_date":" 03/21/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-03-13"},{"id":"93a602fc-fef4-4ca8-ada5-f9aa24df7e29","acronym":"","url":"https://clinicaltrials.gov/study/NCT05720988","created_at":"2023-08-14T10:11:11.619Z","updated_at":"2025-02-25T15:45:00.769Z","phase":"Phase 1","brief_title":"Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia","source_id_and_acronym":"NCT05720988","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • Elzonris (tagraxofusp-erzs)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/03/2024","start_date":" 08/03/2024","primary_txt":" Primary completion: 08/03/2025","primary_completion_date":" 08/03/2025","study_txt":" Completion: 08/03/2026","study_completion_date":" 08/03/2026","last_update_posted":"2024-03-08"},{"id":"9f422a88-402d-4776-a63e-899f8ce422df","acronym":"NCI-2014-01147","url":"https://clinicaltrials.gov/study/NCT02159495","created_at":"2021-01-18T10:03:02.202Z","updated_at":"2024-07-02T16:35:21.732Z","phase":"Phase 1","brief_title":"Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm","source_id_and_acronym":"NCT02159495 - NCI-2014-01147","lead_sponsor":"City of Hope Medical Center","biomarkers":" FLT3 • CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive","tags":["FLT3 • CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CD123R(EQ)28zeta/EGFRt+ T cells • MB-102 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 12/15/2015","start_date":" 12/15/2015","primary_txt":" Primary completion: 12/15/2024","primary_completion_date":" 12/15/2024","study_txt":" Completion: 12/15/2024","study_completion_date":" 12/15/2024","last_update_posted":"2024-01-30"},{"id":"e40ed8d7-48ac-41b5-b29f-5f77dd399916","acronym":"","url":"https://clinicaltrials.gov/study/NCT05032183","created_at":"2023-08-14T10:11:06.622Z","updated_at":"2024-07-02T16:35:33.498Z","phase":"Phase 1/2","brief_title":"Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","source_id_and_acronym":"NCT05032183","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Truxima (rituximab-abbs) • Elzonris (tagraxofusp-erzs) • mercaptopurine • mesna • Hemady (dexamethasone tablets) • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/17/2022","start_date":" 02/17/2022","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-10-16"},{"id":"9263296a-f501-4dcf-9d13-ddd3f6920a7f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05320380","created_at":"2023-08-14T10:11:08.231Z","updated_at":"2024-07-02T16:35:38.286Z","phase":"Phase 1/2","brief_title":"A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat","source_id_and_acronym":"NCT05320380","lead_sponsor":"Children's Oncology Group","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • Vyxeos (cytarabine/daunorubicin liposomal formulation) • fludarabine IV • pivekimab sunirine (PVEK) • Starasid (cytarabine ocfosfate)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2023-09-01"},{"id":"8d195ac4-ff45-457f-b006-0abe5f018000","acronym":"","url":"https://clinicaltrials.gov/study/NCT06006403","created_at":"2023-08-23T15:10:48.638Z","updated_at":"2024-07-02T16:35:38.691Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm","source_id_and_acronym":"NCT06006403","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" IL6 • CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA positive","tags":["IL6 • CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CD123 targeted CAR-NK"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/31/2023","start_date":" 08/31/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2023-08-30"},{"id":"7c0994a9-8277-4f13-b963-37bb1082d426","acronym":"CADENZA","url":"https://clinicaltrials.gov/study/NCT03386513","created_at":"2023-08-14T10:10:58.304Z","updated_at":"2024-07-02T16:35:41.144Z","phase":"Phase 1/2","brief_title":"Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN","source_id_and_acronym":"NCT03386513 - CADENZA","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pivekimab sunirine (PVEK)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 179","initiation":"Initiation: 01/02/2018","start_date":" 01/02/2018","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-08-03"},{"id":"35ca491d-0cc1-434a-914b-6dc84cb52011","acronym":"","url":"https://clinicaltrials.gov/study/NCT05574608","created_at":"2022-10-10T14:05:46.075Z","updated_at":"2024-07-02T16:35:49.544Z","phase":"Phase 1","brief_title":"Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia","source_id_and_acronym":"NCT05574608","lead_sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JD023"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 10/30/2023","primary_completion_date":" 10/30/2023","study_txt":" Completion: 10/30/2024","study_completion_date":" 10/30/2024","last_update_posted":"2023-04-26"},{"id":"23fe5699-b91c-473a-b6f8-99a276ffb074","acronym":"","url":"https://clinicaltrials.gov/study/NCT04272125","created_at":"2021-01-18T20:45:10.451Z","updated_at":"2024-07-02T16:35:50.369Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04272125","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression • IL3RA positive","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"},{"id":"2f6c09fe-648a-43a4-b8de-c7035dd17c75","acronym":"","url":"https://clinicaltrials.gov/study/NCT04265963","created_at":"2021-01-18T20:43:42.945Z","updated_at":"2024-07-02T16:35:50.304Z","phase":"Phase 1/2","brief_title":"CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04265963","lead_sponsor":"Chongqing Precision Biotech Co., Ltd","biomarkers":" CD123 • IL3RA","pipe":" | ","alterations":" CD123 positive • CD123 expression • IL3RA expression • IL3RA positive","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • CD123 expression • IL3RA expression • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 CAR-T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-04-18"},{"id":"b7c01580-5ee3-4f13-b16b-b440889f56d5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04678466","created_at":"2023-08-14T10:11:05.005Z","updated_at":"2024-07-02T16:36:09.693Z","phase":"","brief_title":"Flotetuzumab Expanded Access Program","source_id_and_acronym":"NCT04678466","lead_sponsor":"MacroGenics","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e flotetuzumab (MGD006)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2022-05-30"},{"id":"a8d426ea-8842-4fc1-bfee-96024bf6f5ae","acronym":"APVO436","url":"https://clinicaltrials.gov/study/NCT03647800","created_at":"2021-05-26T19:57:54.811Z","updated_at":"2024-07-02T16:36:17.299Z","phase":"Phase 1b","brief_title":"Study of APVO436 in Patients With AML or MDS","source_id_and_acronym":"NCT03647800 - APVO436","lead_sponsor":"Aptevo Research and Development LLC","biomarkers":" FLT3 • RUNX1 • ASXL1 • IL3RA","pipe":" | ","alterations":" ASXL1 mutation • CD123 positive • IL3RA positive","tags":["FLT3 • RUNX1 • ASXL1 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASXL1 mutation • CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e mipletamig (APVO436)"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 12/13/2018","start_date":" 12/13/2018","primary_txt":" Primary completion: 12/15/2022","primary_completion_date":" 12/15/2022","study_txt":" Completion: 06/15/2023","study_completion_date":" 06/15/2023","last_update_posted":"2022-02-10"},{"id":"3fedea47-3322-47fb-bf06-bb20557b31c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04973618","created_at":"2023-08-14T10:11:06.153Z","updated_at":"2024-07-02T16:36:20.014Z","phase":"Phase 1b","brief_title":"Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML","source_id_and_acronym":"NCT04973618","lead_sponsor":"Aptevo Therapeutics","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • mipletamig (APVO436)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2021-12-01"},{"id":"c5704378-a92a-4e30-87b4-ad54ce93aafa","acronym":"","url":"https://clinicaltrials.gov/study/NCT04796441","created_at":"2021-03-12T15:53:04.530Z","updated_at":"2024-07-02T16:36:33.385Z","phase":"","brief_title":"Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation","source_id_and_acronym":"NCT04796441","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" IFNG • IL6 • TNFA • IL10 • IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IFNG • IL6 • TNFA • IL10 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/16/2020","start_date":" 12/16/2020","primary_txt":" Primary completion: 12/16/2021","primary_completion_date":" 12/16/2021","study_txt":" Completion: 02/16/2022","study_completion_date":" 02/16/2022","last_update_posted":"2021-03-12"},{"id":"1a6210c8-021b-4f65-8ae7-713cab256751","acronym":"","url":"https://clinicaltrials.gov/study/NCT03488862","created_at":"2021-01-18T17:11:10.718Z","updated_at":"2024-07-02T16:36:36.104Z","phase":"","brief_title":"Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients","source_id_and_acronym":"NCT03488862","lead_sponsor":"UNC Lineberger Comprehensive Cancer Center","biomarkers":" KIT • CD33 • CD34 • IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["KIT • CD33 • CD34 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 10/28/2020","primary_completion_date":" 10/28/2020","study_txt":" Completion: 10/28/2020","study_completion_date":" 10/28/2020","last_update_posted":"2021-01-13"},{"id":"c680c5d8-4f65-49d8-aa7d-65b4bcfd55e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04106076","created_at":"2023-03-04T19:03:31.381Z","updated_at":"2024-07-02T16:36:43.310Z","phase":"Phase 1","brief_title":"Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid Leukemia","source_id_and_acronym":"NCT04106076","lead_sponsor":"Cellectis S.A.","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UCART123"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/11/2019","start_date":" 07/11/2019","primary_txt":" Primary completion: 12/05/2019","primary_completion_date":" 12/05/2019","study_txt":" Completion: 12/05/2019","study_completion_date":" 12/05/2019","last_update_posted":"2020-07-14"},{"id":"a0484239-01b6-477b-85f1-0b0d87f142ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03796390","created_at":"2023-08-14T10:11:00.531Z","updated_at":"2024-07-02T16:37:03.898Z","phase":"Phase 1","brief_title":"Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia","source_id_and_acronym":"NCT03796390","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" IL3RA","pipe":" | ","alterations":" CD123 positive • IL3RA positive","tags":["IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 positive • IL3RA positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SENL401"],"overall_status":"Unknown status","enrollment":" Enrollment 15","initiation":"Initiation: 12/26/2018","start_date":" 12/26/2018","primary_txt":" Primary completion: 11/06/2020","primary_completion_date":" 11/06/2020","study_txt":" Completion: 06/06/2021","study_completion_date":" 06/06/2021","last_update_posted":"2019-01-11"}]